<p>摩根大通分析师 Brian Cheng 昨日对 Intellia Therapeutics 维持了卖出评级，并设定了 8.00 美元的目标价。该公司股票昨日收盘价为 14.28 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks，Cheng 是一位 4 星分析师，平均回报率为 6.7%，成功率为 52.55%。Cheng 覆盖医疗保健行业，专注于 Protagonist Therapeutics、Revolution Medicines 和 Protara Therapeutics 等股票。</p>
<p>除了摩根大通，Intellia Therapeutics 还在 5 月 11 日收到了高盛的 Salveen Richter 的卖出评级。然而，昨日摩根士丹利对 Intellia Therapeutics（NASDAQ: NTLA）维持了持有评级。</p>

Intellia治疗

IBBQ

标普生物技术 3 倍做多 - Direxion

<p>摩根大通分析师 Brian Cheng 对 Intellia Therapeutics（NTLA）维持了卖出评级，目标价为 8.00 美元，而该股收盘价为 14.28 美元。Cheng 是一位四星级分析师，平均回报率为 6.7%，成功率为 52.55%。高盛也对 Intellia 发布了卖出评级，而摩根士丹利则维持了持有评级</p>

<p>J.P. Morgan analyst Brian Cheng maintained a Sell rating on Intellia Therapeutics yesterday and set a price target of $8.00. The company’s shares closed yesterday at $14.28.</p>
<div class="lb-trans"><p>摩根大通分析师 Brian Cheng 昨日对 Intellia Therapeutics 维持了卖出评级，并设定了 8.00 美元的目标价。该公司股票昨日收盘价为 14.28 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Cheng is a 4-star analyst with an average return of 6.7% and a 52.55% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Revolution Medicines, and Protara Therapeutics.</p>
<div class="lb-trans"><p>根据 TipRanks，Cheng 是一位 4 星分析师，平均回报率为 6.7%，成功率为 52.55%。Cheng 覆盖医疗保健行业，专注于 Protagonist Therapeutics、Revolution Medicines 和 Protara Therapeutics 等股票。</p>
</div><p>In addition to J.P. Morgan, Intellia Therapeutics also received a Sell from Goldman Sachs’s Salveen Richter in a report issued on May 11. However, yesterday, Morgan Stanley maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA).</p>
<div class="lb-trans"><p>除了摩根大通，Intellia Therapeutics 还在 5 月 11 日收到了高盛的 Salveen Richter 的卖出评级。然而，昨日摩根士丹利对 Intellia Therapeutics（NASDAQ: NTLA）维持了持有评级。</p>
</div>

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

Tip Ranks

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

基因组进步主动型 ETF - Franklin Templeton

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

Wisdomtree BioRevolution Fund ETF

基因改革 ETF - ARK

基因免疫&健康关怀 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

摩根大通

Protagonist治疗

Revolution Medicines

Protara Therapeutic

高盛

摩根士丹利

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

摩根大通仍然对 Intellia 治疗公司（NTLA）维持卖出评级